Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ)
Kunming, CN
Yixintang Pharmaceutical Group Co., Ltd. is a prominent Chinese enterprise primarily managing an extensive network of pharmacies nationwide. The company's operations also encompass the production and retail of a diverse array of items, including raw medicinal ingredients, traditional Chinese herbal medicines, and various health and dietary supplements. Furthermore, it actively participates in pharmaceutical distribution. By January 31, 2020, its retail footprint spanned 7,205 outlets across numerous provinces and municipalities, such as Yunnan, Guizhou, Guangxi, Sichuan, Shanxi, Chongqing, Tianjin, Shanghai, and Qiong. Complementing its brick-and-mortar presence, Yixintang also conducts online sales. Established in 2000 with its headquarters in Kunming, China, the company adopted its current name, Yixintang Pharmaceutical Group Co., Ltd., in June 2019, having previously been called Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.31% | -0.23% | +2.57% | -5.83% | -9.38% | -0.86% | -9.38% | -54.27% | -67.65% | -39.43% | +45.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 0 | -1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-3.7% Q1'26: -7.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+142.1% ★ Q1'26: +14.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+5.0% Q1'26: +14.2% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.3% Q1'26: +6.4% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+7.1% ★ Q1'26: +10.8% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-2.7% ★ Q1'26: -2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×3.04× ★ Q1'26: 3.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.32B
est: 5.73B (-7.2%)
|
6.25B
est: 6.25B (+0.0%)
|
7.75B
est: 7.34B (+5.6%)
|
9.47B
est.
|
10.48B
est: 10.72B (-2.2%)
|
9.18B
est: 10.72B (-14.4%)
|
12.66B
est: 12.62B (+0.3%)
|
14.69B
est.
|
14.59B
est: 17.17B (-15.0%)
|
17.38B
est: 17.83B (-2.5%)
|
17.43B
est: 17.83B (-2.3%)
|
18.00B
est: 18.00B (+0.0%)
|
17.34B
est: 17.20B (+0.8%)
|
18.13B
17.53B – 18.83B
+5.4% YoY
|
19.29B
18.00B – 20.79B
+6.4% YoY
|
20.70B
19.66B – 21.91B
+7.3% YoY
|
25.74B
24.44B – 27.25B
+24.4% YoY
|
| EBITDA |
467.11M
est: 379.08M (+23.2%)
|
520.74M
est: 413.24M (+26.0%)
|
685.88M
est: 485.59M (+41.2%)
|
626.27M
est.
|
862.26M
est: 708.93M (+21.6%)
|
819.74M
est: 708.93M (+15.6%)
|
1.06B
est: 834.72M (+27.5%)
|
971.39M
est.
|
1.33B
est: 1.14B (+17.6%)
|
967.02M
est: 1.18B (-18.0%)
|
1.50B
est: 1.18B (+27.2%)
|
467.71M
est: 1.11B (-58.0%)
|
866.67M
est: 1.06B (-18.5%)
|
1.12B
1.08B – 1.16B
+5.4% YoY
|
1.19B
1.11B – 1.29B
+6.4% YoY
|
1.28B
1.22B – 1.36B
+7.3% YoY
|
1.59B
1.51B – 1.69B
+24.4% YoY
|
| EBIT |
415.57M
est: 341.42M (+21.7%)
|
454.17M
est: 372.19M (+22.0%)
|
612.99M
est: 437.35M (+40.2%)
|
564.05M
est.
|
788.83M
est: 638.49M (+23.5%)
|
745.39M
est: 638.49M (+16.7%)
|
984.87M
est: 751.79M (+31.0%)
|
874.88M
est.
|
1.24B
est: 1.02B (+21.0%)
|
842.36M
est: 1.06B (-20.7%)
|
1.39B
est: 1.06B (+30.5%)
|
358.20M
est: 992.31M (-63.9%)
|
745.35M
est: 947.99M (-21.4%)
|
999.63M
966.26M – 1.04B
+5.4% YoY
|
1.06B
992.28M – 1.15B
+6.4% YoY
|
1.14B
1.08B – 1.21B
+7.3% YoY
|
1.42B
1.35B – 1.50B
+24.4% YoY
|
| Net Income |
346.26M
est: 393.89M (-12.1%)
|
353.38M
est: 420.54M (-16.0%)
|
422.71M
est: 429.43M (-1.6%)
|
568.79M
est.
|
603.92M
est: 637.27M (-5.2%)
|
521.07M
est: 637.27M (-18.2%)
|
789.96M
est: 766.12M (+3.1%)
|
976.51M
est.
|
921.58M
est: 989.48M (-6.9%)
|
549.44M
est: 778.89M (-29.5%)
|
1.01B
est: 778.89M (+29.7%)
|
114.14M
est: 354.43M (-67.8%)
|
263.43M
est: 449.52M (-41.4%)
|
503.05M
337.53M – 668.57M
+11.9% YoY
|
599.45M
377.63M – 821.27M
+19.2% YoY
|
714.55M
667.55M – 768.93M
+19.2% YoY
|
1.57B
1.46B – 1.69B
+119.4% YoY
|
| SGA |
1.23B
est: 1.15B (+6.4%)
|
1.44B
est: 1.26B (+14.8%)
|
1.80B
est: 1.48B (+22.0%)
|
1.90B
est.
|
2.31B
est: 2.15B (+7.3%)
|
2.08B
est: 2.15B (-3.3%)
|
2.56B
est: 2.54B (+0.9%)
|
2.95B
est.
|
2.98B
est: 3.45B (-13.6%)
|
3.36B
est: 3.58B (-6.2%)
|
3.41B
est: 3.58B (-5.0%)
|
3.77B
est: 3.92B (-3.7%)
|
4.94B
est: 3.74B (+32.1%)
|
3.94B
3.81B – 4.10B
+5.4% YoY
|
4.20B
3.92B – 4.52B
+6.4% YoY
|
4.50B
4.28B – 4.77B
+7.3% YoY
|
5.60B
5.32B – 5.93B
+24.4% YoY
|
| EPS |
0.67
est: 0.67 (+0.8%)
|
0.68
est: 0.71 (-4.2%)
|
0.81
est: 0.73 (+11.7%)
|
0.96
est.
|
1.06
est: 1.08 (-1.5%)
|
0.92
est: 1.08 (-14.5%)
|
1.38
est: 1.29 (+6.7%)
|
1.65
est.
|
1.56
est: 1.67 (-6.6%)
|
0.92
est: 1.32 (-30.0%)
|
1.70
est: 1.32 (+29.3%)
|
0.19
est: 0.62 (-69.1%)
|
0.46
est: 0.78 (-41.0%)
|
0.87
0.59 – 1.16
+11.9% YoY
|
1.04
0.66 – 1.43
+19.2% YoY
|
1.24
1.16 – 1.33
+19.2% YoY
|
2.72
2.54 – 2.93
+119.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.00% | 16.3K | 0.49% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 171.7K | 0.39% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 10.3K | 0.44% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 224.9K | 0.06% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 27.7K | 0.46% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 103.6K | 0.29% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 74.7K | 0.28% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 16.3K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.2K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 803.0K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donglei Xiao | Financial Manager | — | male |
| Guowei Ruan | Vice President | — | male |
| Hong Xian Ruan | President & Executive Chairman | — | male |
| Peng Juan Yin | Accounting Supervisor | — | — |
| Yong Zhang | Executive President & Executive Director | — | male |
| Zheng Hong Li | Vice President & Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002727.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
